| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | 0.33% | Goldman Sachs | $29 → $33 | Maintains | Neutral |
| 07/20/2023 | -8.79% | JP Morgan | $28 → $30 | Maintains | Neutral |
| 07/19/2023 | 6.42% | B. Riley Securities | → $35 | Reinstates | Buy → Buy |
| 07/06/2023 | 0.33% | B of A Securities | $26 → $33 | Upgrades | Underperform → Neutral |
| 12/14/2022 | -20.95% | Goldman Sachs | $24 → $26 | Upgrades | Sell → Neutral |
| 07/25/2022 | 0.33% | Jefferies | $36 → $33 | Maintains | Buy |
| 07/25/2022 | 6.42% | B. Riley Securities | $37.5 → $35 | Maintains | Buy |
| 04/11/2022 | — | Exane BNP Paribas | Initiates Coverage On | → Outperform | |
| 03/22/2022 | -23.99% | Goldman Sachs | $28 → $25 | Maintains | Sell |
| 07/26/2021 | 15.54% | Seaport Global | → $38 | Upgrades | Neutral → Buy |
| 07/26/2021 | 21.62% | Keybanc | $43 → $40 | Maintains | Overweight |
| 01/28/2021 | — | Seaport Global | Initiates Coverage On | → Neutral | |
| 01/25/2021 | 30.74% | Keybanc | $39 → $43 | Maintains | Overweight |
| 11/19/2020 | 18.58% | Keybanc | $36 → $39 | Maintains | Overweight |
| 11/17/2020 | -60.47% | B of A Securities | $15 → $13 | Maintains | Underperform |
| 10/26/2020 | 9.46% | Keybanc | $33 → $36 | Maintains | Overweight |
| 10/20/2020 | — | Baird | Reinstates | → Outperform | |
| 10/09/2020 | 0.33% | Jefferies | $32 → $33 | Maintains | Buy |
| 07/27/2020 | -2.71% | Jefferies | $31 → $32 | Maintains | Buy |
| 07/27/2020 | 0.33% | Keybanc | → $33 | Upgrades | Sector Weight → Overweight |
| 04/24/2020 | -8.79% | CFRA | $35 → $30 | Maintains | Buy |
| 04/15/2020 | -42.23% | Goldman Sachs | → $19 | Initiates Coverage On | → Sell |
| 01/31/2020 | 6.42% | CFRA | $34 → $35 | Reiterates | → Buy |
| 01/06/2020 | 12.5% | Jefferies | → $37 | Upgrades | Hold → Buy |
| 10/21/2019 | 6.42% | B. Riley Securities | $29 → $35 | Maintains | Buy |
| 10/16/2019 | -11.83% | Guggenheim | → $29 | Initiates Coverage On | → Buy |
| 04/02/2019 | -23.99% | BMO Capital | $26 → $25 | Maintains | Outperform |
| 02/05/2019 | — | Longbow Research | Downgrades | Buy → Neutral | |
| 12/11/2018 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 12/04/2018 | -27.03% | Jefferies | → $24 | Initiates Coverage On | → Hold |
| 10/22/2018 | -27.03% | BMO Capital | $25 → $24 | Maintains | Outperform |
| 10/22/2018 | -39.19% | Baird | $19 → $20 | Maintains | Neutral |
What is the target price for Gentex (GNTX)?
The latest price target for Gentex (NASDAQ: GNTX) was reported by Goldman Sachs on July 31, 2023. The analyst firm set a price target for $33.00 expecting GNTX to rise to within 12 months (a possible 0.33% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gentex (GNTX)?
The latest analyst rating for Gentex (NASDAQ: GNTX) was provided by Goldman Sachs, and Gentex maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Gentex (GNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gentex, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gentex was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
Is the Analyst Rating Gentex (GNTX) correct?
While ratings are subjective and will change, the latest Gentex (GNTX) rating was a maintained with a price target of $29.00 to $33.00. The current price Gentex (GNTX) is trading at is $32.89, which is within the analyst's predicted range.